How long should you take Osimertinib (Tagressa) to achieve the best effect?

Osimertinib (Osimertinib) is a third-generation oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), mainly used for < /span>EGFRMutation-positive non-small cell lung cancer (NSCLC) patients, including patients with T790M drug-resistant mutations. It selectively inhibits EGFR sensitive mutations and T790M resistant mutations, blocking downstream signaling pathways, thereby inhibiting tumor cell proliferation and inducing apoptosis.

Clinical studies have shown that osimertinib is rapidly absorbed in the body and reaches peak plasma concentration in about 6 hours after oral administration, but it usually takes about 8 days for the drug to reach steady-state concentration. Although the blood drug concentration stabilizes quickly, clinical efficacy requires a certain amount of time to accumulate. In multicenter clinical trials (such as AURA3), most patients begin to observe objective responses (tumor shrinkage or disease stabilization) around 2 months to 3 months, which is generally considered the initial window for evaluating efficacy.

The difference in the time of optimal response is mainly related to individual patient factors, tumor burden, EGFR mutation type and previous treatments. For example, patients with high tumor burden or brain metastases may experience relatively slow response, whereas patients with early diagnosis and high tumor sensitivity may experience significant responses within 1–2 months of treatment. In addition, medication compliance, concomitant medications, and liver and kidney function status also affect how quickly efficacy is achieved.

Therefore, in clinical application, osimertinib usually requires continuous administration at least 2–3 months to initially evaluate the efficacy, and the optimal efficacy may require longer observation and maintenance. During the medication period, patients should undergo regular imaging examinations and condition assessments, as well as monitor blood indicators and adverse reactions to ensure maximum safety and efficacy. The doctor will decide whether to continue treatment or adjust the plan based on the efficacy and tolerability and the patient's specific situation.

Reference materials:https://www.drugs.com/